Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children older than 2 years, or adults of any gender
- People whose cancer cells show a specific marker called CD1a on at least 20% of the abnormal cells, confirmed by laboratory testing
- People diagnosed with a type of blood cancer called T-cell acute lymphoblastic leukaemia or lymphoblastic lymphoma (T-ALL/LL) that has come back or has not responded to treatment — this includes people whose cancer did not go away after at least two rounds of chemotherapy, people who have had one or more relapses after standard treatment, people whose cancer came back after a bone marrow/stem cell transplant, or people whose cancer persisted after chemotherapy in a way that means a transplant is not considered suitable
- People who are not able to have children, or people who commit to using a highly effective form of contraception throughout the study
Who may not be able to join:
- People with serious problems affecting the heart (such as reduced heart pumping function below a certain level), lungs, liver, kidneys, or brain that are not under control
- People who had a bone marrow/stem cell transplant less than 3 months ago, or who still need medication to manage graft-versus-host disease (a complication where transplanted cells attack the body)
- People with uncontrolled epilepsy or a severe condition affecting the brain or nervous system
- People with an active bacterial, fungal, or viral infection that is not being adequately controlled with treatment
- People known to have HIV, or an active hepatitis B or hepatitis C infection
- People who are pregnant or breastfeeding
- People with a serious illness or medical condition that would make it unsafe to follow the trial's treatment plan
- People with a serious autoimmune disease or a condition that significantly weakens the immune system
- People who have taken part in another experimental drug trial within 6 weeks before the trial treatment (called OC-1) would be given
- People with another type of cancer that is not currently under control
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 34 93 403 58 62
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of adverse events grade III-IV; Incidence of severe Cytokine release syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS); Non-relapse treatment-related mortality (NRM); Number of adverse events of special interest (AESI); Assessment of the immunological homeostasis; Incidence of the treatment-related dermatological events; Number of patients developing dose limiting toxicity (DLT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.